NASDAQ
ZVSA

ZyVersa Therapeutics Inc.

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

ZyVersa Therapeutics Inc. Stock Price

Vitals

Today's Low:
$0.1104
Today's High:
$0.1288
Open Price:
$0.1104
52W Low:
$0.11
52W High:
$25
Prev. Close:
$0.111
Volume:
8145052

Company Statistics

Market Cap.:
$4.34 million
Book Value:
0.848
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-59.59%
Return on Equity TTM:
-4011.44%

Company Profile

ZyVersa Therapeutics Inc. had its IPO on 2022-12-12 under the ticker symbol ZVSA.

The company operates in the Healthcare sector and Biotechnology industry. ZyVersa Therapeutics Inc. has a staff strength of 7 employees.

Stock update

Shares of ZyVersa Therapeutics Inc. opened at $0.11 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.11 - $0.13, and closed at $0.13.

This is a +15.77% increase from the previous day's closing price.

A total volume of 8,145,052 shares were traded at the close of the day’s session.

In the last one week, shares of ZyVersa Therapeutics Inc. have slipped by -8.87%.

ZyVersa Therapeutics Inc.'s Key Ratios

ZyVersa Therapeutics Inc. has a market cap of $4.34 million, indicating a price to book ratio of 0 and a price to sales ratio of 0.

In the last 12-months ZyVersa Therapeutics Inc.’s revenue was $0 with a gross profit of $0 and an EBITDA of $-16161874. The EBITDA ratio measures ZyVersa Therapeutics Inc.'s overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, ZyVersa Therapeutics Inc.’s operating margin was 0% while its return on assets stood at -59.59% with a return of equity of -4011.44%.

In Q2, ZyVersa Therapeutics Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

ZyVersa Therapeutics Inc.’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-7.47 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ZyVersa Therapeutics Inc.’s profitability.

ZyVersa Therapeutics Inc. stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.

ZyVersa Therapeutics Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$31.99 million
Total Liabilities
$10.48 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

ZyVersa Therapeutics Inc. ended 2024 with $31.99 million in total assets and $0 in total liabilities. Its intangible assets were valued at $31.99 million while shareholder equity stood at $20.06 million.

ZyVersa Therapeutics Inc. ended 2024 with $0 in deferred long-term liabilities, $10.48 million in other current liabilities, 2367.00 in common stock, $-86978221.00 in retained earnings and $11.90 billion in goodwill. Its cash balance stood at $228693.00 and cash and short-term investments were $228693.00. The company’s total short-term debt was $59,625 while long-term debt stood at $0.

ZyVersa Therapeutics Inc.’s total current assets stands at $1.12 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $8.14 million and inventory worth $0.

In 2024, ZyVersa Therapeutics Inc.'s operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, ZyVersa Therapeutics Inc. paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.13
52-Week High
$25
52-Week Low
$0.11
Analyst Target Price
$

ZyVersa Therapeutics Inc. stock is currently trading at $0.13 per share. It touched a 52-week high of $25 and a 52-week low of $25. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.18 and 200-day moving average was $0 The short ratio stood at 0.22 indicating a short percent outstanding of 0%.

Around 5443.8% of the company’s stock are held by insiders while 2796.7% are held by institutions.

Frequently Asked Questions About ZyVersa Therapeutics Inc.

The stock symbol (also called stock or share ticker) of ZyVersa Therapeutics Inc. is ZVSA

The IPO of ZyVersa Therapeutics Inc. took place on 2022-12-12

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
Coherent Inc (COHR)
$32.76
-0.07
-0.21%
$853.15
2.65
+0.31%
$2.13
-0.11
-4.91%
$1075.35
-77.25
-6.7%
$478.8
-15.15
-3.07%
$8.04
-0.07
-0.86%
$71.88
-0.71
-0.98%
$27.86
0.31
+1.13%
$1990.85
-19.65
-0.98%
$57.06
-0.17
-0.3%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Address

2200 North Commerce Parkway, Weston, FL, United States, 33326